RBC Capital Reiterates Sector Perform on Aardvark Therapeutics, Maintains $6 Price Target
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.
Stocks · News reference
Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent. This is unchanged from the same period last year.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
RBC Capital analyst Brian Abrahams reiterates Aardvark Therapeutics (NASDAQ:AARD) with a Sector Perform and maintains $6 price target.
Law firm Lowey Dannenberg is investigating Aardvark Therapeutics for potential federal securities violations related to its lead drug ARD-101. The company paused its Phase 3 trial in February 2026 due to cardiac safety concerns and faced an FDA clinical hold in May 2026, causing significant stock price declines and shareholder losses.
Scholar Rock surged 11.9% after FDA approved ISEMBYLD for SMA; Scinai, Intercont and Rum led premarket gainers, while Picocela fell.
Grabar Law Office announced investigations into shareholder claims against four companies: Aardvark Therapeutics for allegedly misleading statements about drug safety leading to 56% stock decline; Flotek Industries for misrepresentations regarding a terminated Puerto Rico power project; GoDaddy for failing to disclose impact of promotional pricing on bookings; and Hub Group for material financial statement misstatements. Long-term shareholders may pursue corporate reforms and compensation.